Compare Lowe`s Companies Inc (LOW) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Repligen Corporation Common Stock — how do they compare? Lowe`s Companies Inc trades at $190.5 (market cap $105.89B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Lowe`s Companies Inc is far larger — about 9.5× Repligen Corporation Common Stock's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Repligen Corporation Common Stock for 0 Days on average.
| LOW | RGEN | |
|---|---|---|
Market Cap | $105.89B | $11.14B |
Volume | 3,104,115 | 1,259,263 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $194.57 |
52-Week Low | $179.50 | $102.87 |
Typical Hold Time | 98 Days | 0 Days |
Enterprise Value | $144.74B | $11.02B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.36, up 1.5% with recent earnings beats but facing industry headwinds. The stock shows bearish technical signals despite positive analyst sentiment with a $244.09 consensus target. Revenue declined to $83.67B in 2025, though net margins remain healthy at 7.35%. Recent drone delivery initiatives with DoorDash and Alphabet aim to enhance competitiveness amid a challenging home improvement market.
LOW presents a value opportunity with reasonable P/E (15.95) and strong cash flow, but risks include declining revenue trends, high debt levels, and housing market sensitivity. Wall Street maintains bullish ratings (61% buy) despite near-term pressure, suggesting potential upside if execution improves.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
